Rifapentine demonstrates efficacy for pregnant women, including those with HIV
Date: 03/14/2020
“A woman is more likely to develop tuberculosis (TB) in the first 90 days after she has a baby than at any other time in her life, especially if she has HIV,” Jyoti S. Mathad, MD, MS, assistant professor of medicine, obstetrics and gynecology, at Weill Cornell Medical College, told Healio. “WHO currently recommends that all people with HIV, including pregnant women, take medications to prevent TB, but a recent trial raised concerns about the most common regimen used during pregnancy: 6 months of daily isoniazid. That's a problem, because the more cutting-edge treatments, such as 3 months of weekly isoniazid and rifapentine (3HP), which has improved safety and adherence in nonpregnant people, has not been tested at all in pregnant women.”